Treatment of advanced gastric cancer with cetuximab plus chemotherapy followed by surgery. Report of a case

被引：2

作者：

Casadei, Riccardo ^{[1
]}

Rega, Daniela ^{[1
]}

Pinto, Carmine ^{[2
,3
]}

Monari, Francesco ^{[1
]}

Ricci, Claudio ^{[1
]}

Sciannamea, Gianluca ^{[1
]}

Minni, Francesco ^{[1
]}

机构：

[1] Univ Bologna, Policlin S Orsola Malpighi, Alma Mater Studiorum, Dipartimento Emergenza Urgenza Chirurg Gen & Trap, I-40138 Bologna, Italy

[2] Univ Bologna, Policlin S Orsola Malpighi, Alma Mater Studiorum, Dipartimento Ematol, I-40138 Bologna, Italy

[3] Univ Bologna, Policlin S Orsola Malpighi, Alma Mater Studiorum, Oncol & Med Lab, I-40138 Bologna, Italy

来源：

TUMORI JOURNAL | 2009年 / 95卷 / 06期

关键词：

gastric cancer; neoadjuvant therapy; cetuximab; gastrectomy; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; PROGNOSTIC-FACTORS; SUPPORTIVE CARE; PHASE-II; CARCINOMA; FLUOROURACIL; METHOTREXATE; OXALIPLATIN; COMBINATION; THERAPY;

D O I：

10.1177/030089160909500627

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prognosis of patients affected by advanced gastric cancer who did not undergo non-curative resection is extremely poor. We report a case of a 26-year-old woman affected by gastric cancer with peritoneal carcinosis in whom surgical treatment was not considered. The patient was enrolled in the Italian phase II trial of cetuximab (Erbitux, Merck KGaA, Darmstadt, Germany), a monoclonal antibody, in combination with docetaxel and cisplatin chemotherapy Restaging of the tumor showed progressive regression, so the patient underwent a total gastrectomy. The patient is alive, well and disease-free ten months after surgery. The good result achieved in this patient provides interesting prospects for chemotherapy combined with cetuximab, followed by surgery.

引用

页码：811 / 814

页数：4

共 27 条

[11]

MURAD AM, 1993, CANCER, V72, P37, DOI 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO

[12]

2-P

[13]

NAKAMURA K, 1992, CANCER, V70, P1030, DOI 10.1002/1097-0142(19920901)70:5<1030::AID-CNCR2820700504>3.0.CO

[14]

2-C

[15]

*NCCN, NCCN GASTR CANC PAN

[16] Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy [J].

Persiani, R ;

D'Ugo, D ;

Rausei, S ;

Sermoneta, D ;

Barone, C ;

Pozzo, C ;

Ricci, R ;

LA Torre, G ;

Picciocchi, A .

JOURNAL OF SURGICAL ONCOLOGY, 2005, 89 (04) :227-236

[17] Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) [J].

Pinto, C. ;

Di Fabio, F. ;

Siena, S. ;

Cascinu, S. ;

Llimpe, F. L. Rojas ;

Ceccarelli, C. ;

Mutri, V. ;

Giannetta, L. ;

Giaquinta, S. ;

Funaioli, C. ;

Berardi, R. ;

Longobardi, C. ;

Piana, E. ;

Martoni, A. A. .

ANNALS OF ONCOLOGY, 2007, 18 (03) :510-517

[18]

PINTO C, 2008, J CLIN ONCOL, V26, pS15

[19] RANDOMIZED COMPARISON OF FLUOROURACIL, EPIDOXORUBICIN AND METHOTREXATE (FEMTX) PLUS SUPPORTIVE CARE WITH SUPPORTIVE CARE ALONE IN PATIENTS WITH NONRESECTABLE GASTRIC-CANCER [J].

PYRHONEN, S ;

KUITUNEN, T ;

NYANDOTO, P ;

KOURI, M .

BRITISH JOURNAL OF CANCER, 1995, 71 (03) :587-591

[20]

RODER JD, 1993, CANCER-AM CANCER SOC, V72, P2089, DOI 10.1002/1097-0142(19931001)72:7<2089::AID-CNCR2820720706>3.0.CO

← 1 2 3 →